Biotech IPO “Class of 2010″ Continues to Impress

Posted in Exits IPOs M&As

Matt Herper over at FORBES suggested I update and repost the “Glimmer of Hope” “Class of 2010″ biotech IPOs blog post, which I’ve now done, and the performance continues to impress:

The average and median performance of this “Class” is 33% and 21%, respectively – which is markedly better than all the recent prior classes’ performance.  Ventrus, Aegerion, AVEO, Complete Genomics, and Trius have all appreciated by more than 50% since their IPO.

Pretty impressive returns for the top half the group.   I’m still skeptical about most new IPOs, but much of this group certainly seems to be performing well.

This entry was posted in Exits IPOs M&As. Bookmark the permalink.
  • Anonymous

    Considering the S&P 500 was up about 30% over the same time period, the 2010 class of biotech IPOs have faired fairly well.  If you take out both outliers  – TNGN and VTUS – the 2010 biotech IPO numbers looks even better.  

    Hopefully the door will swing open even more in 2011 for biotech IPOs!

  • clinical studies india

    Two days before one aunty asked to me what is biotech and that benefits like that.. This blogs is very helpful for her i think.. I will share this also.. Thanks for sharing this information with us..

  • Pingback: Structuring a Biotech Liquidity Thesis

  • Pingback: A Look Back at 2010-2011 Class of Biotech IPOs: Not Dead Yet |